Loandepot, Inc. current report, 10 October 2022

Full document

Business Context and Reporting Period

loanDepot, Inc. filed this Form 8-K on October 10, 2022, reporting a material agreement amendment involving its indirect subsidiary, loanDepot.com, LLC. The filing was signed on October 14, 2022.

loanDepot.com, LLC amended its Mortgage Loan Participation Sale Agreement with JPMorgan Chase Bank, National Association. Under the agreement, loanDepot may sell participation interests in designated pools of fully amortizing, first-lien residential mortgage loans eligible to back securities and may later deliver related securities to JPMorgan in exchange for participation certificates.

Financial Metrics and Liquidity

The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, operating, or other quantitative financial metrics.

Material Changes Versus the Prior Comparable Period

Amendment No. 10 makes certain technical changes and, most significantly, extends the termination date of the Mortgage Loan Participation Sale Agreement to November 11, 2022. No prior-period financial comparison is included.

Guidance, Outlook, Risks, Contingencies, and Unusual Items

  • The amendment preserves loanDepot’s ability to sell qualifying mortgage-loan participation interests to JPMorgan during the extended term.
  • The filing does not disclose pricing, transaction volume, minimum or maximum commitments, collateral amounts, fees, financial covenants, or termination conditions beyond the stated extension date.
  • The agreement’s full terms should be reviewed because the filing’s description is expressly qualified by reference to Exhibit 10.1.

Facts Investors Should Verify

  • Review Exhibit 10.1 for the complete terms and technical changes in Amendment No. 10.
  • Confirm whether the agreement was further extended, terminated, or replaced after November 11, 2022.
  • Assess the volume and economics of mortgage-loan participation sales conducted under the agreement.
  • Review subsequent filings for any effects on funding capacity, mortgage production, liquidity, or counterparty exposure to JPMorgan.